Determining the Effect of Abacavir on Platelet Activation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01886638
Recruitment Status : Completed
First Posted : June 26, 2013
Last Update Posted : May 22, 2015
Information provided by (Responsible Party):
Bayside Health

June 24, 2013
June 26, 2013
May 22, 2015
August 2013
June 2014   (Final data collection date for primary outcome measure)
Change in Phosphorylated Vasodilator Stimulated Phosphoprotein (P-VASP) assay [ Time Frame: Baseline, day 15 and day 48 ]
Same as current
Complete list of historical versions of study NCT01886638 on Archive Site
  • Platelet aggregation [ Time Frame: Baseline, Day 15 and day 48 ]
    Measurement of the degree of platelet aggregation in response to collagen related peptide and thrombin receptor-agonist peptide
  • Platelet specific collagen receptor glycoprotein VI (GPVI) [ Time Frame: Baseline, Day 15 and Day 48 ]
    Measurement of the expression and shedding of platelet specific collagen receptor GPVI
Same as current
Not Provided
Not Provided
Determining the Effect of Abacavir on Platelet Activation
Determining the Effect of Abacavir on Platelet Activation in Virologically Suppressed HIV Positive Men: an Open Label Interventional Study

HIV positive patients have a two fold increased risk of developing cardiovascular disease (such as heart attacks and strokes). Cardiovascular disease appears to be due in part to both HIV and the side effects from anti-HIV medications.

Abacavir (an important component of current HIV treatment regimens) is one medication shown to be associated with an increase the risk of heart attacks in some studies. The mechanism by which abacavir does this is unknown.

We hypothesise that abacavir is leading to heart disease by interacting with platelets, which then form blood clots within the arteries supplying the heart, the subsequent blockage of the artery causing a heart attack.

This study aims to determine if abacavir increases the activity (or "stickiness") of platelets, and thus provide evidence as to how it may be promoting heart attacks.

It will consist of 23 HIV positive men who currently have well controlled HIV. Participants will take abacavir for 15 days in addition to their usual anti-HIV medications. A blood sample to assess platelet activity will be taken at baseline, following the 15 days of therapy (i.e. at the time of maximal abacavir effect) and again after a 28 day washout period (to determine if any effects are reversible).

Not Provided
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • HIV
  • Cardiovascular Disease
Drug: Abacavir
Other Name: Ziagen
Experimental: Abacavir
Abacavir 600mg (as two 300mg tablets) once daily for 15 days
Intervention: Drug: Abacavir
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
October 2014
June 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • > 18 years of age
  • Male
  • HIV positive
  • Stable non-abacavir containing anti-retroviral regimen
  • Undetectable HIV Viral load

Exclusion Criteria:

  • HLA-B*57*01 allele positivity
  • Previous allergy to abacavir
  • Known cardiovascular disease
  • High Baseline cardiovascular risk (Framingham risk score > 20%)
  • Current or recent antiplatelet therapy
  • Pre-existing platelet or bleeding disorder (i.e. Thrombophilia, Thrombocytopenia, Von willebrands disease, Haemophilia)
  • Significant Chronic liver disease
  • Current Methadone use
Sexes Eligible for Study: Male
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
ACTRN12613000570785 ( Registry Identifier: ANZCTR )
Not Provided
Not Provided
Bayside Health
Bayside Health
Not Provided
Principal Investigator: Jennifer Hoy, MBBS FRACP Alfred health, Monash University
Principal Investigator: Janine Trevillyan, MBBS FRACP Alfred Health, Monash university
Bayside Health
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP